Measures Correlated | Spearman’s rho | p |
---|---|---|
Patient and MD global PsA activity | 0.76 | < 0.01 |
SJC and MD global PsA activity | 0.74 | < 0.01 |
TJC and MD global PsA activity | 0.68 | < 0.01 |
Patient global arthritis and HAQ | 0.61 | < 0.01 |
TJC and HAQ | 0.89 | < 0.01 |
SJC and HAQ | 0.54 | 0.01 |
Patient global arthritis and SF-36 PCS | 0.75 | < 0.01 |
HAQ and SF-36 PCS | 0.84 | < 0.01 |
HAQ and PASI | 0.41 | 0.08 |
Patient global arthritis and PASI | 0.52 | 0.02 |
Patient global skin and PASI | 0.53 | 0.02 |
MD global skin and PASI | 0.52 | 0.02 |
Patient global skin and SF-36 PCS | 0.38 | 0.13 |
PASI and SF-36 PCS | 0.56 | 0.02 |
mNAPSI and MD nail global | 0.93 | < 0.01 |
mNAPSI and patient nail global | 0.55 | 0.01 |
mNAPSI and PASI | 0.38 | 0.10 |
mNAPSI and SF-36 PCS | 0.53 | 0.02 |
Patient global nail and SF-36 PCS | 0.56 | 0.02 |
mNAPSI and patient global arthritis | 0.42 | 0.07 |
mNAPSI and TJC | 0.53 | 0.02 |
mNAPSI and SJC | 0.44 | 0.05 |
mNAPSI: modified Nail Psoriasis Severity Index; HAQ: Health Assessment Questionnaire; SJC: swollen joint count; TJC: tender joint count; PASI: Psoriasis Area and Severity Index; SF-36: Medical Outcome Study Short-Form 36; PCS: physical component summary.